Evaluation of Interleukin 17 A Level and Lipid Profile in Diabetic Female Patients Treated by Metformin and Glimepiride in Kirkuk City Iraq
Fatma Mustafa Mohammed and Chateen I. Ali Pambuk
College of Dentistry / University of Tikrit
Corresponding Author E-mail: dr.chatin2@yahoo.com
Abstract: The study was conducted on patients with type 2 diabetes in Kirkuk governorate for the period from March 2016 to July 2016. The aim of the study was to evaluate some variables for diabetics who were referred to clinics and specialized laboratories in Kirkuk governorate. The study included 124 female samples ranging in age from 38-69 years. These samples were divided into 4 groups. A group of 40 healthy samples representing the control group were free of diabetes and chronic diseases. Group (B) of the 18 sample, and included patients with type II diabetes are treated with the drug Glimepiride . And group (C) of 29 samples of diabetic patients treated with metformin and group (D) 37 samples of diabetic patients treated with metformin and Glimepiride together. The results of the present study showed that there were significant statistical differences (p≤ 0.05) for the body mass in general in patients with Type 2 diabetes mellitus when compared with healthy control. Also, there were in statistically significant increase (p≤ 0.05) in HbA1c and blood glucose for diabetic patients in the three groups compared to healthy females. The results of the current study showed that interleukin 17 was higher in diabetic patients in general, especially in the group C, D with a significant level (p≤ 0.05) compared to the healthy. As for the fat level a significant levels were recorded (p≤ 0.05) (p≤ 0.01) . There was a significant overall increase in both TG LDL VLDL CH and a decrease in HDL.
Keywords: Interleukin 17 A; Metformin; Glimepiride; diabetes m; Lipid profile Back to TOC